[
  {
    "ts": null,
    "headline": "Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company’s recent acquisition announcement. Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA […]",
    "url": "https://finnhub.io/api/news?id=fa3b251b0056667dde96f847ad5cd6d9e10c4dd09c1396c9b029ad3ba5eacbe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752071174,
      "headline": "Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)",
      "id": 135835733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company’s recent acquisition announcement. Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA […]",
      "url": "https://finnhub.io/api/news?id=fa3b251b0056667dde96f847ad5cd6d9e10c4dd09c1396c9b029ad3ba5eacbe4"
    }
  }
]